

American Society for Pain Management Nursing (ASPMN®)
26th National Conference
Louisville, Kentucky
September 8, 2016

A Call for Balance in Pain Care & Prescription Drug Abuse Prevention: Legislation & Policy

Michael Barnes, Esq., Executive Director, Center for Lawful Access and Abuse Deterrence (CLAAD)

Wade Delk, Government Affairs Director, ASPMN®

Marsha Stanton, Ph.D., R.N., Past President, ASPMN®

Disclosure

CLAAD's funders include pharmaceutical companies, treatment centers, and laboratories, and are disclosed on its website, www.claad.org.

CLAAD is managed by DCBA Law & Policy. To avoid conflicts of interest, DCBA adheres to the District of Columbia Rules of Professional Conduct §§ 1.7-1.9.

Preview

★ Introduction

★ Recent Activity

- Federal Government
 - Executive
 - Legislative
- State Government
- Private Sector
- Black Market

★ Steps To Achieve Greater Balance

★ Conclusion

Federal Executive Activity

★ CDC guidelines

- Recommended for primary care
- CMS and insurer adoption is occurring
- Call for transition to maintenance on buprenorphine

★ National Pain Strategy

★ FDA Opioids Action Plan

- REMS
- Abuse-deterrent guidance
- Long-term studies

★ Buprenorphine (opioid dependence)

- Qualified nurse practitioners and physician assistants
- Higher patient limit

Federal Legislation

- ★ Comprehensive Addiction & Recovery Act
 - New federal task force to recommend best practices for pain management
 - Acknowledges the value of abuse-deterrent medications (CMS line extension definition clarified)
- ★ Bill to foster a broader transition to abuse-deterrent medications (no consensus achieved)
- ★ Protecting Our Infants Act
- ★ Ensuring Patient Access and Effective Drug Enforcement Act (Raid/Regulate)
- ★ CLAAD to push bill for criminal justice reform/access to health care in jails

State Legislation

- ★ Safer prescribing standards (heavy push to adopt CDC guidelines)
 - Opioids for pain
 - Buprenorphine for opioid dependence
- ★ Prescriber education requirements
- ★ Prescription monitoring programs
 - Mandatory data checks
 - Privacy concerns
 - DEA and state/local law enforcement access
 - Access to private data for commercial purposes
- ★ Registration/licensure and regulation
 - Pain clinics
 - Opioid dependence (buprenorphine) clinics
- ★ Good Samaritan, naloxone laws

Private Sector Activity

★ New treatments for pain and addiction

- Non-opioid
- Abuse-deterrent opioid
- Lower doses of buprenorphine for pain
- Implant for opioid dependence
- Injectables for pain and opioid dependence under development

★ FDA citizen petitions

- Equivalent or improved abuse-deterrent qualities
- Require offering a prescription for FDA-approved naloxone when prescribing opioids

★ Insurer denials of treatment for pain and addiction, including definitive urine drug testing

★ Insurance industry and plaintiffs' attorneys active in lobbying and influencing media

Black Market Activity

★ Narco-capitalists exploiting strong demand

- Inability to find qualified and willing providers, and harassment and denials at pharmacies
 - Pain
 - Addiction
 - Anxiety, insomnia, etc.

★ Counterfeit/analog opioids (*e.g.*, fentanyl and oxycodone) and benzodiazepines


★ Heroin price, purity, and availability

Steps To Achieve Greater Balance

- ★ Monitoring at federal and state levels
- ★ Reporting to membership and calls to action
- ★ Rapid response through letters and meetings
- ★ Collaboration and coordination with other organizations

State Advocacy

- Advocacy
 - Federal Legislation
 - Federal Regulations
 - State Advocacy
- Join ASPMN[®]
Click here for membership details



Supported by a grant from Purdue Pharma L.P.

Please select the state and click search for you to find the members in particular state.

Conclusion

★ Thanks to ASPMN®

★ Thank You

★ Questions and Discussion

★ Contacts:

-  @claad_coalition, @mcbtweets, LinkedIn.com/in/michaelcbarnes
- wade@aspmn.org
- stanton_marsha@yahoo.com